Novo Nordisk to buy IP rights to Neose technology
This article was originally published in Scrip
Executive Summary
Novo Nordisk is to acquire the intellectual property rights related to Neose Technologies's proprietary GlycoPEGylation technology for $21 million. The Danish company says the acquisition is in line with its strategy to expand in general haemophilia. Novo Nordisk is using the technology to develop recombinant blood clotting factors FVIIa, FVIII and FIX. GlycoPEGylation enables selective addition of polyethylene glycol (PEG) to sugar chains to extend and customise protein half-life.
You may also be interested in...
Innovation not M&A to drive Bayer growth in LatAm
Laura Gonz�lez-Molero will be celebrating her first anniversary as President of Bayer HealthCare Pharmaceuticals, Latin America this month. With Bayer posting total sales of €1.05bnin Latin America in 2014, up 13% over 2013, Ms Gonz�lez-Molero should be pleased with a successful inaugural year. Resolute in her belief that innovation, "part of Bayer's DNA," will determine the company's long-term success in Latin America, rather than growth through acquisition, Ms Gonz�lez-Molero talks to Scrip about her personal ambitions for the company and the region.
2010 Scrip 100 - Is Anvisa a friend of innovators?
A decade since its formation Anvisa, Brazil's medicines regulator, has shaken up the country's framework for ensuring drug quality. Yet the agency's approaches to drug pricing and registration have left some multinationals wanting, reports Sita Shah.
Elan raises $1.5 billion
Elan is raising $1.5 billion in bonds to refinance its existing debt and for general corporate purposes, it says.